de Oliveira, Fabricio Ferreira, Bertolucci, Paulo Henrique Ferreira, Chen, Elizabeth Suchi, Smith, Marilia de Arruda Cardoso

To evaluate correlations of pharmacological treatment with cognitive and behavioral symptoms in patients with dementia due to Alzheimer’s disease with low schooling, subjects were assessed for demographic features, neuropsychiatric symptoms, cognitive decline, functionality, caregiver burden, APOE haplotypes and pharmacological treatment. Among 217 patients, use of cholinesterase inhibitors with or without Memantine was associated with less […]

Chan, Tuen-Ching, Luk, James Ka-Hay, Shea, Yat-Fung, Lau, Ka-Hin, Chan, Felix Hon-Wai, Yu, Gabriel Ka-Kui, Chu, Leung-Wing

Background: Previous meta-analyses have suggested that antipsychotics are associated with increased mortality in dementia patients with behavioral and psychological symptoms (BPSD). Subsequent observational studies, however, have produced conflicting results. In view of this controversy and the lack of any suitable pharmacological alternative for BPSD, this study aimed to investigate the relationship between continuous use of […]

Camargos, Einstein F., Louzada, Luciana L., Quintas, Juliana L., Naves, Janeth O.S., Louzada, Fernando M., Nóbrega, Otávio T.

Objectives: There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD). We tested the efficacy and safety of trazodone to treat SD in patients with AD. Design: We conducted a double-blind, randomized and controlled trial during periods of 7–9 days at baseline […]

Beglinger, Leigh J., Adams, William H., Langbehn, Douglas, Fiedorowicz, Jess G., Jorge, Ricardo, Biglan, Kevin, Caviness, John, Olson, Blair, Robinson, Robert G., Kieburtz, Karl, Paulsen, Jane S.

Background: The objective of this study was to evaluate citalopram for executive functioning in Huntington’s disease (HD).; Methods: The study was randomized, double-blind, and placebo-controlled. Thirty-three adults with HD, cognitive complaints, and no depression (Hamilton Depression [HAM-D] rating scale ≤ 12) were administered citalopram 20 mg or placebo (7 visits, 20 weeks), with practice and […]

Barak, Yoram, Plopski, Igor, Tadger, Shelly, Paleacu, Diana

Background: Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer’s disease (AD), but safety warnings abound. Escitalopram was investigated since citalopram has demonstrated some effectiveness in AD. We compared escitalopram and risperidone for psychotic symptoms and agitation associated with AD.; Methods: Inpatients with AD, who had been hospitalized because of […]

Banerjee, Sube, Hellier, Jennifer, Dewey, Michael, Romeo, Renee, Ballard, Clive, Baldwin, Robert, Bentham, Peter, Fox, Chris, Holmes, Clive, Katona, Cornelius, Knapp, Martin, Lawton, Claire, Lindesay, James, Livingston, Gill, McCrae, Niall, Moniz-Cook, Esme, Murray, Joanna, Nurock, Shirley, Orrell, Martin, O'Brien, John, Poppe, Michaela, Thomas, Alan, Walwyn, Rebecca, Wilson, Kenneth, Burns, Alistair

Background: Depression is common in dementia but the evidence base for appropriate drug treatment is sparse and equivocal. We aimed to assess efficacy and safety of two of the most commonly prescribed drugs, sertraline and mirtazapine, compared with placebo.; Methods: We undertook the parallel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidepressants […]

Ballard, Clive, Hanney, Maria Luisa, Theodoulou, Megan, Douglas, Simon, McShane, Rupert, Kossakowski, Katja, Gill, Randeep, Juszczak, Edmund, Yu, Ly-Mee, Jacoby, Robin

Background: Data from 12-week placebo-controlled trials have led to mounting concerns about increased mortality in patients with Alzheimer’s disease (AD) who are prescribed antipsychotics; however, there are no mortality data from long-term placebo-controlled trials. We aimed to assess whether continued treatment with antipsychotics in people with AD is associated with an increased risk of mortality.; […]